CENTOGENE Little Child Looking out of Window With Binoculars

CentoGenome® – See Diagnostics In a New Way

A comprehensive view into patients’ genetic data using whole genome sequencing. CentoGenome is the most complete solution to diagnose genetically complex and undiagnosed cases with the highest level of certainty.

Order a test  Why choose CentoGenome?

CENTOGENE’s Whole Genome Sequencing Service

Whole genome sequencing (WGS) identifies almost all changes in a patient’s DNA by sequencing both the entire protein coding and the non-coding regions of the genome.

Today there are millions of patients suffering from misdiagnosed or undiagnosed genetic diseases as a result of insufficient genetic testing. Although in certain cases approaches like single gene testing, panel testing, or microarrays can identify the cause of a disease, these analyses are ultimately limited and can fail to reveal the full genetic cause. WGS, in contrast, overcomes such limitations and is the only test that can detect nearly all types of disease-causing genetic variants in one single test.1,2

Most studies on genetic diseases have been heavily biased towards variants in gene coding regions, but this only accounts for approx. 1–2% of a patient’s entire genome. Recently, however, a growing body of studies have demonstrated that clinical WGS offers a more comprehensive analysis than WES and can provide molecular diagnosis where WES can not.1-5 Non-coding variants, such as intergenic and intronic pathogenic variants, are growing in number and importance, spanning from sequence variants to more complex structural variations.5,6

CentoGenome, CENTOGENE’s whole genome sequencing service, offers the most comprehensive one-step solution with the highest diagnostic yield.


Distinctive product offering centered around high-quality genetic testing

Strong presence in and access to countries with a high prevalence of rare diseases

CentoCard provides easy logistics for central testing

Rare disease-centric Bio/Databank generates best-in-class medical insights

Deep expertise in rare, metabolic, and neurodegenerative diseases, as well as multiomics enables better diagnostics

Why Choose CentoGenome?

CENTOGENE Diagnostics Whole Exome Sequencing Icon Report

Our Expertise

Best-in-class insights powered by the world’s largest rare disease-centric Bio/Databank from the leader and trusted partner in rare disease diagnostics

CENTOGENE Diagnostics Whole Exome Sequencing Icon DNA Search

Your Questions Answered

Unparalleled genome coverage and diagnostic power in a single test, providing fast track to diagnosis and optimized therapies

CENTOGENE Diagnostics Whole Exome Sequencing Icon Heart

Our Commitment

Life-long support by a team dedicated to improving the lives of patients with rare diseases


CentoGenome MOx – Explore the Next Generation of Whole Genome Sequencing

Learn more

Unparalleled Genome Coverage and Diagnostic Power

CentoGenome offers unparalleled genome coverage and captures one of the most extensive ranges of disease-causing genetic variants in a single test. Our WGS solution is a highly effective diagnostic tool – delivering high diagnostic yields across a variety of rare genetic conditions. CentoGenome is especially valuable in patients for whom previous WES produced negative results, with a recent study showing its ability to solve up to 30% of WES negative cases.5

By choosing this comprehensive and rapid analysis, you can save your patients valuable time to diagnosis and consequently may help to further refine prognosis and enhance therapeutic decision-making.

Features & Performance

Highly uniform genome and mitochondrial genome coverage
  • Mean depth >30x
  • Uniform coverage of the entire nuclear genome (>20,000 genes) and mitochondrial genome (37 genes), with >97% of the genome covered at ≥10x
Advanced detection of nearly all types of variants in one single test Highly sensitive and specific detection of SNVs, InDels, SVs including CNVs, and mtDNA variants with heteroplasmy ≥15%
  • Sensitivity
    SNVs and InDels (≤ 55 bp) >99.7%
    SVs/CNVs >98.0%
  • Specificity of >99.9% is guaranteed for all reported variants*

SNVs: single nucleotide variants; InDels: small insertions/deletions; CNVs: copy number variations; SVs: structural variants; mtDNA: variants in mitochondrial DNA;
*Variants with low quality and/or unclear zygosity are confirmed by orthogonal methods (i.e., SNVs and InDels by Sanger sequencing; CNVs by Multiplex ligation-dependent probe amplification, MPLA; quantitative polymerase chain reaction, qPCR; or chromosomal microarray, CMA)

When is WGS Recommended?

WGS is recommended especially for the diagnosis of patients with heterogeneous phenotypes, unclear or atypical clinical symptoms, or with a long list of prior differential diagnoses, or who have exhausted other genetic testing options. We particularly recommend CentoGenome for patients when:

The symptoms are very broad, complex, or unspecific, not pointing towards specific disease or typical phenotype, as:

  • Clinical or genetic heterogeneity (e.g., intellectual disability/developmental delay, epilepsy, muscular dystrophies/muscular disorders, ataxia, neuropathies, cardiomyopathies, skeletal dysplasias, immunodeficiency, deafness, blindness)
  • Diseases or patients with atypical clinical presentations or phenotypes (e.g., patient with intracranial aneurysm due to PKD1 gene – polycystic kidney disease)
  • Patients with 'blended' clinical presentations and clinical suspicion of dual diagnosis (e.g., patient with deafness and ichthyosis, intellectual disability and severe immunodeficiency)
  • Suspected of a microdeletion or microduplication syndrome (e.g., patients with neurodevelopmental delay, multiple dysmorphisms and/or malformations, growth delay)
  • Suspected mitochondrial disease (e.g., patient with muscular weakness, cardiomyopathy, visual problems)

Prior testing did not provide a conclusive diagnosis, like:

  • Patient with autosomal dominant spastic paraplegia and with a negative result for the gene panel
  • Patient with neurodevelopmental delay, with similarly affected siblings, and a negative testing with microarrays and WES
  • Any case with suspected genetic disease and negative WES

A fast diagnosis is a medical necessity and there is not always the time for serial testing strategies, as seen with:

  • Patients severely ill for whom a diagnosis may direct or alter medical management (e.g., children with seizures, hypotonia, neurological abnormalities, and a rapidly deteriorating clinical status)
  • Newborns, babies and children where a rapid diagnosis is crucial for prognosis and treatments decisions (e.g., critically ill newborns and children in the neonatal and pediatric intensive care NICU and PICU)

Our most recent study, where we present the largest cohort of patients with WGS performed in a clinical setting to date, demonstrated the diagnostic strength of CentoGenome as the most comprehensive genetic test and its superiority to WES.5 The results also support that WGS should be considered the 'standard of care' for genetic testing, as well as a first-line stand-alone test for rare disease patients.

CentoGenome helps you tackle challenging and undiagnosed patient cases across all stages of life and covers a broad spectrum of disorders encompassing >7,000 rare diseases.

Tailored Services to Your Patient's Needs 

We offer flexible testing options and additional services that allow you to tailor the CentoGenome analysis to you patient’s needs, as for example WGS for ongoing pregnancies with fetal abnormalities for prenatal diagnostics and expedited WGS for critically ill patients that need rapid and precise genetic diagnosis.

Committed to Improving the Lives of Patients With Rare Diseases

CentoGenome is paired with life-long diagnostic support via a free-of-charge and proactive reclassification program, as well as an affordable case-level reanalysis in case of uncertain or negative results. WGS diagnostic yield is continuously increasing due to the rapid rate of new gene-disease discoveries, and it is estimated that about 10-20% of undiagnosed patients can be diagnosed by reclassification and genomic data reanalysis.7

When a rapid diagnosis is a medical necessity

A rapid diagnosis can be critical for timely and appropriate medical intervention. Several recent studies demonstrate how the high diagnostic yield and short turnaround time of WGS enables improved clinical decision making in critically ill newborn infants and children in the Neonatal Intensive Care Units (NICU) or Pediatric Intensive Care Units (PICU).8-12 CentoGenome, with a turnaround time of down to 15 days, acts as a comprehensive and accurate tool that will potentially improve critical decision making when used as a first-line test for diagnosing critically ill newborns or children

Options & Additional Services

Turnaround time Regular ≤20 business days
FAST ≤15 business days
Testing design
  • Solo, Duo, Trio and Trio Plus
  • Mitochondrial genome analysis is performed only for the index patient and maternal samples
Prenatal testing*
  • Prioritization and expediting at each stage of the process
  • Reduce turnaround time, up to ≤15 business days
  • Includes cell culture and maternal contamination testing
Genome wide analysis of structural variants CentoArray® (chromosomal microarray analysis, CMA)
Raw data Raw data available free-of-charge for download (FASTQ, BAM, VCF files) along with filtered and annotated variant table (XLS file) for further research
Life-long diagnostic support
  • Proactive variant-level re-evaluation and reclassification at no extra cost**
  • Case-level reanalysis and medical reinterpretation at an affordable cost in case of uncertain or negative results

Solo: only the affected index patient is tested; Duo: index patient and affected or unaffected family member are tested; Trio: index patient
and two family members, affected or unaffected are tested; PLUS: additional family member beyond Trio is tested
*More details at Prenatal Testing
**More details at Variant Reclassification Program

Best-in-Class Insights by the Leader & Trusted Partner in Rare Disease Diagnostics

In WGS, data analysis and identifying the disease-causing variants among millions of variants is still a challenge. We have the experience of analyzing tens of thousands of clinical genomes/exomes from patients worldwide, and with CentoGenome we can help you to diagnose complex and unsolved cases by finding the clinically important variants.

When choosing our WGS services, physicians, patients, and partners can feel confident that they will receive high-quality sequencing combined with best data analysis and interpretation, documented in comprehensive medical reports. By combining deep phenotype data with genotype data using our advanced bioinformatics pipeline and state-of-the-art artificial intelligence (AI) algorithms, we accurately identify and prioritize disease-causing variants to deliver best-in-class clinical interpretation and reporting. The quality of our medical reports is based on our clinical interpretation expertise, best-in-class curated variant data from our Bio/Databank, and international best-practice guidelines. A team of highly trained clinical geneticists and scientists interpret the data and cross-check every medical report. All historical high-quality classifications are curated and codified in our Bio/Databank, which is a reference for diagnostic decisions and classifications. This data repository covers a wide range of ethnicities, unique variant data, and multiomic data from more than 120 countries.

Our medical reports are phenotype-driven and focused on reporting findings related to the patient’s clinical presentation/patient’s indications. For the best WGS results, it is crucial to obtain specific and detailed clinical information about the patient and ideally also include further family members. Several studies have shown that the chances of having a clinically useful genetic result increases with the quality of the clinical information provided.5,14 

Test reports always contain clear actionable clinical results, recommendations, and follow-up options. They are phenotype-driven and focused on reporting findings related to the patient’s clinical presentation/patient’s indications.

CentoGenome MOx

Complete the Clinical Picture With Biochemistry

Order a test

Integrated genomic and biochemical testing facilitates the decision on the pathogenicity of clinical variants leading to higher diagnostic yield

Biochemical testing allows for orthogonal confirmation of disease – accelerating the path to a diagnosis by avoiding stepwise testing​

Multiomics provides a complete clinical picture – enabling the assessment of disease severity and thus accelerating personalized treatments​

Additional Information & Resources


MOx – Advancing Rare Disease Patient Care With Multiomic Solutions

Watch the on-demand webinar now to gain insights into our multiomics revolution – a multidimensional approach looking at each patient from different angles to combine deep knowledge and insights for […]

Apr 07, 2022
  • Multiomics
  • WGS
  • WES
  • Metabolic Disorders

Rewrite the Future of Rare Diseases With Multiomics

Our speakers, Maximilian Schmid M.D., Chief Commercial Officer – Diagnostics, and Prof. Peter Bauer M.D., Chief Genomic Officer, will highlight the power of multiomics in establishing a complete […]

Nov 04, 2021
  • Multiomics
  • WES
  • NGS
  • Mutation Database

Webinar de CentoGenome - ‘Una mirada al poder de la Secuenciación del Genoma Completo’

Acompáñenos en nuestro CentoWebinar ‘Una mirada al poder de la secuenciación del genoma completo.’ A lo largo del webinar, nuestro presentador el Dra. Aida M. Bertoli-Avella, MD le proporcionará una […]

Dec 08, 2020
  • WGS
  • WES
  • NGS

Scientific Publications

Linking Seizures and Amino Acid Homeostasis

Seizures are part of the phenotypic spectrum in numerous rare disorders, but the underlying pathophysiology is rarely understood. For a novel seizure syndrome, the transmembrane transport of certain […]

Oct 04, 2021
  • WES
  • WGS
  • Mutation Database
  • Neurology

Combining Genetic Insights and Therapeutic Efforts

The delineation of a novel rare disease is commonly a stand-alone research project. An international consortium, in which CENTOGENE played a major role, showcased how disease discovery can […]

Sep 30, 2021
  • WGS
  • WES
  • Mutation Database

Collaborative Discovery of Gene-Disease Associations

The delineation of novel genetic disorders is facilitated by the formation of global research consortia. By actively contributing to collaborative efforts, CENTOGENE has supported dozens of […]

Jul 08, 2021
  • WES
  • WGS
  • Mutation Database
  • Neurology


CENTOGENE CentoGenome Case Study English PDF

CentoGenome – Case Study

Case study: Diagnosis of Gitelman Syndrome

CENTOGENE Sample Report CentoGenome Trio Index Positive PDF

CentoGenome MOx Trio – Index, Positive Secondary and Additional Findings

CARRIER STATUS CONFIRMED – Likely pathogenic variant identified

CENTOGENE Sample Report CentoGenome Trio Mother Positive PDF

CentoGenome MOx Trio – Mother, Carrier Status Confirmed, Negative Secondary Findings

CARRIER STATUS CONFIRMED – Likely pathogenic variant identified

CENTOGENE Sample Report CentoGenome Trio Father Negative PDF

CentoGenome MOx Trio – Father, Carrier Status Confirmed, Positive Secondary Findings

CARRIER STATUS CONFIRMED – Likely pathogenic variant identified

Get in Touch With Our Customer Support

Our consultation service is available in several languages.

+49 (0) 381 80 113 - 416

Mon. – Fri. 7 a.m. – 8 p.m. CEST

Sat. 8 a.m. – 12 p.m. CEST

Contact Us

For our US Partners:

+1 (617) 580 - 2102

Mon. – Fri. 9 a.m. – 5:30 p.m. EST

Contact Us


1Lionel et al. 2018, PMID: 28771251; 2Sanghvi et al. 2018, PMID: 9144510; 3Clark et al. 2018; PMID: 30002876; 4Stavropoulos et al. 2016, PMID: 28567303; 5Bertoli-Avella et al. 2020, PMID: 32860008; 6Bick et al. 2019, PMID: 31023718; 7Kingsmore et al. 2019, PMID: 31564432; 8Petrikin et al. 2018, PMID: 29449963; 9Soden et al. 2014; PMID: 25473036; 10Van Diemen et al. 2017, PMID: 28939701; 11Willig et al. 2015, PMID: 25937001; 14Köhler et al. 2019, PMID: 30476213; 15Miller et al. 2021, PMID: 34012069; 16Richards et al. 2015, PMID: 25741868; 17Clinical Genome Resource. https://www.clinicalgenome.org/ [15/02/2022]; 18Matthijs et al. 2026, PMID: 26508566